Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous MSCs in Living Donor Kidney Transplant
NCT03478215Phase 2Active, not recruiting
- Sponsor
- Houston Methodist Research Institute
- Start
- Dec 2016
- Primary completion
- Dec 2025
- Modality
- Mesenchymal Stem Cells
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Provacel in kidney transplant rejection (2 arms), sponsored by Houston Methodist Research Institute. Primary endpoint: Number of participants without any infusional toxicity at 24 hours. Started Dec 2016; status: active, not recruiting.
02
Drugs
Provacel
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT03478215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03478215.